<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03268499</url>
  </required_header>
  <id_info>
    <org_study_id>VIR-14-07</org_study_id>
    <nct_id>NCT03268499</nct_id>
  </id_info>
  <brief_title>TACE Emulsion Versus Suspension</brief_title>
  <official_title>Lipiodol-based Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Randomized Controlled Trial of Aqueous Cisplatin Emulsion Versus Cisplatin Particle Suspension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese University of Hong Kong</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study was to evaluate the safety and efficacy of using the new formulation&#xD;
      (Lipiodol-cisplatin suspension) for TACE in the treatment of HCC as compared to the&#xD;
      conventional formulation (Lipiodol-cisplatin emulsion). This is a prospective,&#xD;
      parallel-group, open-label randomized, phase II study that is conducted in accordance to the&#xD;
      Declaration of Helsinki and international standards of Good Clinical Practice, and approved&#xD;
      by the institutional review board. Eligible patients were randomized into either a treatment&#xD;
      arm of Lipiodol-cisplatin suspension or a control arm of Lipiodol-cisplatin emulsion with a&#xD;
      1:1 ratio.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Transcatheter arterial chemoembolization (TACE) has been playing an important role in the&#xD;
      treatment algorithm for patients with multifocal or large intrahepatic lesions not eligible&#xD;
      for surgical resection, transplantation, or local ablative therapy. In Hong Kong, the TACE&#xD;
      regimen currently being utilized in the great majority of hospitals is based on an aqueous&#xD;
      form of cisplatin (1mg per mL) mixed in a one-to-one ratio by volume with Lipiodol to form a&#xD;
      relatively large volume of 40mL emulsion at 20mg cisplatin as the maximum dose. Although TACE&#xD;
      with this regimen has been shown to be effective in prolonging overall survival, there is&#xD;
      probably room for further improvement because the objective tumor response rate is limited to&#xD;
      39%. One of the approaches to improve the treatment effectiveness of TACE could be to&#xD;
      increase the dose of chemotherapeutic agent. In the United States, the most common regimen of&#xD;
      chemotherapeutic agent in TACE is the mixture of cisplatin 100mg, doxorubicin 50mg, and&#xD;
      mitomycin C 10mg, dissolved in 10ml of water-soluble contrast medium, then emulsified in an&#xD;
      equivalent volume of lipiodol to form a 20mL emulsion. A relatively new regimen was&#xD;
      introduced, in which a relatively high dose of cisplatin up to 100mg in particle form was&#xD;
      given as a suspension in 20mL of Lipiodol, this regimen has been used and found to achieve an&#xD;
      improved objective tumor response rate of 51%.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 2016</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to progression (TTP)</measure>
    <time_frame>within 30 days of a treatment procedure</time_frame>
    <description>The interval between the randomization date and the date of radiological progression, including intralesional progression, extralesional progression, or extra-hepatic progression.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">368</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>Lipiodol-cisplatin suspension</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Lipiodol-cisplatin emulsion</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>The procedure of TACE is the same irrespective of which regimen is used.</description>
    <arm_group_label>Lipiodol-cisplatin emulsion</arm_group_label>
    <arm_group_label>Lipiodol-cisplatin suspension</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Written informed consent&#xD;
&#xD;
          2. Age above 18 years&#xD;
&#xD;
          3. HCC unsuitable for resection or ablation&#xD;
&#xD;
          4. Child-Pugh A cirrhosis&#xD;
&#xD;
          5. Eastern Cooperative Oncology Group performance score 0 or 1&#xD;
&#xD;
          6. BCLC A or B&#xD;
&#xD;
          7. No previous treatment for HCC except for liver resection&#xD;
&#xD;
          8. HCC diagnosed by typical enhancement patterns on cross sectional imaging or histology.&#xD;
&#xD;
          9. No extra-hepatic involvement on non-enhanced CT thorax and triphasic contrast enhanced&#xD;
             CT abdomen.&#xD;
&#xD;
         10. No invasion of portal vein or hepatic vein&#xD;
&#xD;
         11. Massive expansive tumor morphology with measurable lesion on CT (characterized by&#xD;
             well-defined spherical or globular configuration, with or without tumor capsule or&#xD;
             satellite lesions)&#xD;
&#xD;
         12. Total tumor mass &lt; 50% liver volume&#xD;
&#xD;
         13. Size of any individual tumor &lt;= 12cm in largest dimension&#xD;
&#xD;
         14. Serum creatinine &lt; 130 umol/L or Creatinine clearance &gt; 55 ml/min.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known active malignancy within the last 3 years&#xD;
&#xD;
          2. History of acute tumor rupture presenting with hemo-peritoneum&#xD;
&#xD;
          3. Biliary obstruction not amenable to percutaneous or endoscopic drainage&#xD;
&#xD;
          4. Child-Pugh B or C cirrhosis&#xD;
&#xD;
          5. History of hepatic encephalopathy&#xD;
&#xD;
          6. Intractable ascites not controllable by medical therapy&#xD;
&#xD;
          7. History of variceal bleeding within last 3 months&#xD;
&#xD;
          8. Infiltrative tumor morphology (characterized by ill- defined tumor margin and&#xD;
             amorphous configuration) or diffuse tumor morphology (characterized by large number of&#xD;
             small nodules)&#xD;
&#xD;
          9. Incorrectable Arterio-portal venous shunt affecting &gt;1 hepatic segment on CT&#xD;
&#xD;
         10. Arterial-hepatic venous shunt with hepatic vein opacified in arterial phase on CT&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Simon Yu</last_name>
    <role>Principal Investigator</role>
    <affiliation>DIIR, CUHK, Hong Kong</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Carmen Wong</last_name>
    <phone>(852) 3505 3210</phone>
    <email>carmenwongsp@cuhk.edu.hk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Pui Man Chong</last_name>
    <phone>(852) 3505 3211</phone>
    <email>siuman@cuhk.edu.hk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Imaging and Interventional Radiology, Prince of Wales Hospital, The Chinese University of Hong Kong</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carmen Wong</last_name>
      <phone>(852)3505 3210</phone>
      <email>carmenwongsp@cuhk.edu.hk</email>
    </contact>
    <contact_backup>
      <last_name>Pui Man Chong</last_name>
      <phone>(852)3505 3211</phone>
      <email>siuman@cuhk.edu.hk</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Hong Kong</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>August 29, 2017</study_first_submitted>
  <study_first_submitted_qc>August 29, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 31, 2017</study_first_posted>
  <last_update_submitted>November 9, 2020</last_update_submitted>
  <last_update_submitted_qc>November 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese University of Hong Kong</investigator_affiliation>
    <investigator_full_name>Simon Yu</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

